I'm David Dai. Thank you for joining our inaugural Virtual Oncology Day today. We continue our session with Kura Oncology. It's our great pleasure to have Troy Wilson, President and CEO of Kura Oncology with us. If we move beyond that initial indication, David, and think about frontline combinations, we are excited to be advancing ziftomenib in combination with the standards of